Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.
Primary Purpose
Obesity
Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
microdialysis catheter
microdialysis catheter
Sponsored by

About this trial
This is an interventional basic science trial for Obesity focused on measuring obesity, pharmacokinetic, ertapenem, meropenem
Eligibility Criteria
Inclusion Criteria:
- Hospitalized patients 18 years or older requiring elective surgical intervention (open or laparoscopic surgery) at intraabdominal organs
- BMI more or even 40
- written informed consent
Exclusion Criteria:
- BMI < 40
- pregnancy or lactation in women
- emergency surgery
- history of serious allergy or intolerance to β-lactam antibiotics
- systemic antimicrobial therapy with ceftazidime (internal standard of high-performance liquid chromatography / mass spectrometry) within a 7 days period prior to study entry
- ongoing intraabdominal infections
- terminal illness
- severe diseases of the liver, e.g. cirrhosis of the liver with ALT or AST > 6 x upper limit of normal (ULN) and bilirubin > 3 x ULN
- severe renal insufficiency with a creatinine clearance ≤30 mL/min.
- neutrophil count < 1000 cells/mm3
- platelets < 75000 cells/mm3
- coagulation studies (INR) > 1.5 x ULN
- ongoing chemotherapy and/or radiotherapy
- ongoing therapy with valproin acid (in case of ertapenem administration).
Sites / Locations
- University of Ulm, Dept. of Visceral Surgery
- University of Ulm
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Ertapenem
Meropenem
Arm Description
Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L Free and bound plasma concentration of ertapenem or meropenem in mg/L
Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
Outcomes
Primary Outcome Measures
Unbound concentration of ertapenem and meropenem in fatty tissue and peritoneal fluid
Secondary Outcome Measures
Number of Adverse Events (total and per patient)
Number of Serious Adverse Events (total and per patient)
Number of Suspected Unexpected Serious Adverse Reactions (SUSARs)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01407965
Brief Title
Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.
Official Title
Offene, Monozentrische, Nicht Kontrollierte Und Nicht Randomisierte Phase IV-Studie Zur Bestimmung Der Pharmakokinetik Von Carbapenemen in adipösen Patienten.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Ulm
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Tissue kinetics of ertapenem and meropenem in fatty tissue, intraperitoneal fluid and plasma.
Detailed Description
The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, pharmacokinetic, ertapenem, meropenem
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ertapenem
Arm Type
Experimental
Arm Description
Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L
Free and bound plasma concentration of ertapenem or meropenem in mg/L
Arm Title
Meropenem
Arm Type
Experimental
Arm Description
Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
Intervention Type
Procedure
Intervention Name(s)
microdialysis catheter
Intervention Description
Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
Intervention Type
Procedure
Intervention Name(s)
microdialysis catheter
Intervention Description
Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
Primary Outcome Measure Information:
Title
Unbound concentration of ertapenem and meropenem in fatty tissue and peritoneal fluid
Time Frame
within 24 h after administration
Secondary Outcome Measure Information:
Title
Number of Adverse Events (total and per patient)
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 3 weeks
Title
Number of Serious Adverse Events (total and per patient)
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 3 weeks
Title
Number of Suspected Unexpected Serious Adverse Reactions (SUSARs)
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hospitalized patients 18 years or older requiring elective surgical intervention (open or laparoscopic surgery) at intraabdominal organs
BMI more or even 40
written informed consent
Exclusion Criteria:
BMI < 40
pregnancy or lactation in women
emergency surgery
history of serious allergy or intolerance to β-lactam antibiotics
systemic antimicrobial therapy with ceftazidime (internal standard of high-performance liquid chromatography / mass spectrometry) within a 7 days period prior to study entry
ongoing intraabdominal infections
terminal illness
severe diseases of the liver, e.g. cirrhosis of the liver with ALT or AST > 6 x upper limit of normal (ULN) and bilirubin > 3 x ULN
severe renal insufficiency with a creatinine clearance ≤30 mL/min.
neutrophil count < 1000 cells/mm3
platelets < 75000 cells/mm3
coagulation studies (INR) > 1.5 x ULN
ongoing chemotherapy and/or radiotherapy
ongoing therapy with valproin acid (in case of ertapenem administration).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doris Henne-Bruns, PhD
Organizational Affiliation
University of Ulm
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mathias Wittau, Dr.
Organizational Affiliation
University of Ulm
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Ulm, Dept. of Visceral Surgery
City
Ulm
ZIP/Postal Code
89075
Country
Germany
Facility Name
University of Ulm
City
Ulm
ZIP/Postal Code
89075
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
27795367
Citation
Wittau M, Paschke S, Kurlbaum M, Scheele J, Ly NS, Hemper E, Kornmann M, Henne-Bruns D, Bulitta JB. Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e00952-16. doi: 10.1128/AAC.00952-16. Print 2017 Jan.
Results Reference
derived
PubMed Identifier
26248353
Citation
Wittau M, Scheele J, Kurlbaum M, Brockschmidt C, Wolf AM, Hemper E, Henne-Bruns D, Bulitta JB. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery. Antimicrob Agents Chemother. 2015 Oct;59(10):6241-7. doi: 10.1128/AAC.00259-15. Epub 2015 Jul 27.
Results Reference
derived
Learn more about this trial
Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.
We'll reach out to this number within 24 hrs